Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VIZIMPRO (DACOMITINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VIZIMPRO
NDA
Get alerts
DACOMITINIB | N211288 | PFIZER INC
3 strengths
3 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
DMF
Approvals
Label
Products
Patent Timeline
3 unique patents by expiration date
All strengths
15MG
30MG
45MG
Expired (2)
Active (1)
Today
2026
2027
2028
2029
2030
2031
2032
2033
Today
7772243
Sep. 27, 2032
10596162
Feb. 2, 2026
10603314
Feb. 2, 2026
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 15MG
RLD
3 patents
0 exclusivities
▴
TABLET;ORAL | Approved: Sep 27, 2018
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7772243
Sep 27, 2032
—
Yes
Yes
—
—
10596162
Feb 2, 2026
—
—
—
U-3338
ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION
—
10603314
Feb 2, 2026
—
—
—
U-3337
ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
—
#002 — 30MG
RLD
3 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Sep 27, 2018
#003 — 45MG
RLD
3 patents
0 exclusivities
▾
TABLET;ORAL | Approved: Sep 27, 2018